Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Garyphallia Poulakou & Helen Giamarellou. (2008) Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens. Expert Opinion on Investigational Drugs 17:5, pages 749-771.
Read now
Read now
Jomy Joseph & Keith A Rodvold. (2008) The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opinion on Pharmacotherapy 9:4, pages 561-575.
Read now
Read now
David P Nicolau. (2008) Carbapenems: a potent class of antibiotics. Expert Opinion on Pharmacotherapy 9:1, pages 23-37.
Read now
Read now
Alberto E. Fica & Nancy J. Abusada. (2008) Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency. Scandinavian Journal of Infectious Diseases 40:11-12, pages 983-985.
Read now
Read now
Philip D Lister. (2007) Carbapenems in the USA: focus on doripenem. Expert Review of Anti-infective Therapy 5:5, pages 793-809.
Read now
Read now
Ioannis P Kioumis, Joseph L Kuti & David P Nicolau. (2007) Intra-abdominal infections: considerations for the use of the carbapenems. Expert Opinion on Pharmacotherapy 8:2, pages 167-182.
Read now
Read now
Douglas N Fish. (2006) Meropenem in the treatment of complicated skin and soft tissue infections. Therapeutics and Clinical Risk Management 2:4, pages 401-415.
Read now
Read now
Steven J. Edwards, Cathy E. Emmas & Helen E. Campbell. (2005) Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Current Medical Research and Opinion 21:5, pages 785-794.
Read now
Read now
Peter Lanbeck, Inga Odenholt & Otto Paulsen. (2002) Antibiotics Differ in Their Tendency to Cause Infusion Phlebitis: A Prospective Observational Study. Scandinavian Journal of Infectious Diseases 34:7, pages 512-519.
Read now
Read now
Articles from other publishers (49)
Emily N. Larsen, Nicole Marsh, Gabor Mihala, Michelle King, Matthew Zunk, Amanda J. Ullman, Samantha Keogh, Tricia M. Kleidon & Claire M. Rickard. (2022) Intravenous antimicrobial administration through peripheral venous catheters – establishing risk profiles from an analysis of 5252 devices. International Journal of Antimicrobial Agents 59:4, pages 106552.
Crossref
Crossref
Mahila Monajati, Shahram Ala, Masoud Aliyali, Roya Ghasemian, Fatemeh Heidari, Mohammad Ahanjan, Siavash Moradi, Ali Sharifpour, Mojtaba Mojtahedzadeh & Ebrahim Salehifar. (2021) Clinical Effectiveness of a High Dose Versus the Standard Dose of Meropenem in Ventilator-associated Pneumonia Caused by Multidrugresistant Bacteria: A Randomized, Single-blind Clinical Trial. Infectious Disorders - Drug Targets 21:2, pages 274-283.
Crossref
Crossref
Vanda Ho, Felecia Tay, Jia En Wu, Lionel Lum & Paul Tambyah. (2020) The Case for Intermittent Carbapenem Dosing in Stable Haemodialysis Patients. Antibiotics 9:11, pages 815.
Crossref
Crossref
Xiangqing Song, Yi Wu, Lizhi Cao, Dunwu Yao & Minghui Long. (2019) Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation. Frontiers in Microbiology 10.
Crossref
Crossref
Gerda Wurpts, Werner Aberer, Heinrich Dickel, Randolf Brehler, Thilo Jakob, Burkhard Kreft, Vera Mahler, Hans F. Merk, Norbert Mülleneisen, Hagen Ott, Wolfgang Pfützner, Stefani Röseler, Franziska Ruëff, Helmut Sitter, Cord Sunderkötter, Axel Trautmann, Regina Treudler, Bettina Wedi, Margitta Worm & Knut Brockow. (2019) Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics. Allergo Journal International 28:5, pages 121-151.
Crossref
Crossref
Gerda Wurpts, Werner Aberer, Heinrich Dickel, Randolf Brehler, Thilo Jakob, Burkhard Kreft, Vera Mahler, Hans F. Merk, Norbert Mülleneisen, Hagen Ott, Wolfgang Pfützner, Stefani Röseler, Franziska Ruëff, Helmut Sitter, Cord Sunderkötter, Axel Trautmann, Regina Treudler, Bettina Wedi, Margitta Worm & Knut Brockow. (2019) S2k-Leitlinie: Diagnostik bei Verdacht auf eine Betalaktamantibiotika-Überempfindlichkeit. Allergo Journal 28:5, pages 19-51.
Crossref
Crossref
Ichiro Nakakura, Yoshihiko Ogawa, Kota Sakakura, Kaori Imanishi, Kazuyuki Hirota, Yasuaki Shimatani, Tomoko Uehira, Shoji Nakamori, Rumi Sako, Toshiyuki Doi & Kunio Yamazaki. (2017)
IMP-6 Carbapenemase-Producing
Enterobacteriaceae
Bacteremia Successfully Treated with Amikacin-Meropenem in Two Patients
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37:10, pages e96-e102.
Crossref
Crossref
Denise H. Rhoney & Greene Shepherd. 2017. Seizures in Critical Care. Seizures in Critical Care
321
341
.
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
99
102
.
Blanca Noguerado-Mellado, Celia Pinto Fernández, Rafael Pineda-Pineda, Patricia Martínez Lezcano, Alberto Álvarez-Perea & Manuel De Barrio Fernández. (2014) Cross-reactivity between carbapenems: Two case reports. The Journal of Allergy and Clinical Immunology: In Practice 2:6, pages 816-817.
Crossref
Crossref
Arun Mattappalil & Kari A. Mergenhagen. (2014) Neurotoxicity with Antimicrobials in the Elderly: A Review. Clinical Therapeutics 36:11, pages 1489-1511.e4.
Crossref
Crossref
Akihiro Tanaka, Kenshi Takechi, Shinichi Watanabe, Mamoru Tanaka, Katsuya Suemaru & Hiroaki Araki. (2013) Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem. International Journal of Clinical Pharmacy 35:5, pages 683-687.
Crossref
Crossref
Han Yee Neo, Keng Teng Tan & Yew Yoong Ding. (2013) Higher than expected rates of seizures associated with the use of ertapenem in older hospitalized patients. Journal of Clinical Gerontology and Geriatrics 4:1, pages 17-21.
Crossref
Crossref
Ivan Chytra, Martin Stepan, Jan Benes, Petr Pelnar, Alexandra Zidkova, Tamara Bergerova, Richard Pradl & Eduard Kasal. (2012) Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Critical Care 16:3, pages R113.
Crossref
Crossref
April D. Miller, Amanda M. Ball, P. Brandon Bookstaver, Emily K. Dornblaser & Charles L. Bennett. (2012) Epileptogenic Potential of Carbapenem Agents: Mechanism of Action, Seizure Rates, and Clinical Considerations. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31:4, pages 408-423.
Crossref
Crossref
Tore Midtvedt. 2011. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
491
508
.
A. Pallett & K. Hand. (2010) Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. Journal of Antimicrobial Chemotherapy 65:Supplement 3, pages iii25-iii33.
Crossref
Crossref
Denise H. Rhoney & Panayiotis N. Varelas. 2010. Seizures in Critical Care. Seizures in Critical Care
307
340
.
Vasilios D. Kouranos, Drosos E. Karageorgopoulos, George Peppas & Matthew E. Falagas. (2009) Comparison of adverse events between oral and intravenous formulations of antimicrobial agents: a systematic review of the evidence from randomized trials. Pharmacoepidemiology and Drug Safety 18:10, pages 873-879.
Crossref
Crossref
George G. Zhanel, Nzeera Ketter, Ethan Rubinstein, Ian Friedland & Rebecca Redman. (2009) Overview of Seizure-Inducing Potential of Doripenem. Drug Safety 32:9, pages 709-716.
Crossref
Crossref
Robert P. Baughman. (2009) The Use of Carbapenems in the Treatment of Serious Infections. Journal of Intensive Care Medicine 24:4, pages 230-241.
Crossref
Crossref
Jason Hoffman, Jason Trimble & Gretchen M. Brophy. (2008) Safety of Imipenem/Cilastatin in Neurocritical Care Patients. Neurocritical Care 10:3, pages 403-407.
Crossref
Crossref
Jane Frumin & Jason C Gallagher. (2009) Allergic Cross-Sensitivity Between Penicillin, Carbapenem, and Monobactam Antibiotics: What are the Chances?. Annals of Pharmacotherapy 43:2, pages 304-315.
Crossref
Crossref
Robert G. Masterton. (2009) The new treatment paradigm and the role of carbapenems. International Journal of Antimicrobial Agents 33:2, pages 105.e1-105.e8.
Crossref
Crossref
Jie Gu & Yanyan Huang. (2009) Effect of concomitant administration of meropenem and valproic acid in an elderly chinese patient. The American Journal of Geriatric Pharmacotherapy 7:1, pages 26-33.
Crossref
Crossref
Philip Toltzis, Michael Dul, Mary Ann O’Riordan, David Melnick, Mathew Lo & Jeffrey Blumer. (2009) Meropenem use and colonization by antibiotic-resistant Gram-negative bacilli in a pediatric intensive care unit*. Pediatric Critical Care Medicine 10:1, pages 49-54.
Crossref
Crossref
Jeffery A. Engelhardt. (2008) Predictivity of animal studies for human injection site reactions with parenteral drug products. Experimental and Toxicologic Pathology 60:4-5, pages 323-327.
Crossref
Crossref
Marek A. Mirski & Panayiotis N. Varelas. (2008) Seizures and Status Epilepticus in the Critically Ill. Critical Care Clinics 24:1, pages 115-147.
Crossref
Crossref
Karim Lakhal, Brice Lortat‐Jacob, Catherine Neukirch, Olivier Pajot & Michel Wolff. (2012) Safe Use of Meropenem in a Patient with a Possible Nonimmediate Allergy to Imipenem. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27:9, pages 1334-1338.
Crossref
Crossref
George G Zhanel, Ryan Wiebe, Leanne Dilay, Kristjan Thomson, Ethan Rubinstein, Daryl J Hoban, Ayman M Noreddin & James A Karlowsky. (2007) Comparative Review of the Carbapenems. Drugs 67:7, pages 1027-1052.
Crossref
Crossref
Peter Linden. (2007) Safety Profile of Meropenem. Drug Safety 30:8, pages 657-668.
Crossref
Crossref
S. Fudio, A. Carcas, E. Pinana & R. Ortega. (2006) Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. Journal of Clinical Pharmacy and Therapeutics 31:4, pages 393-396.
Crossref
Crossref
Lisa Saidel‐Odes, Abraham Borer, Klaris Riesenberg, Rozalia Smolyakov & Francisc Schlaeffer. (2006) History of Cerebrovascular Events: A Relative Contraindication to Ertapenem Treatment. Clinical Infectious Diseases 43:2, pages 262-263.
Crossref
Crossref
. 2006. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions
638
641
.
Jose M. TelladoSamuel E. Wilson. (2005) Empiric Treatment of Nosocomial Intra-Abdominal Infections: A Focus on the Carbapenems. Surgical Infections 6:3, pages 329-343.
Crossref
Crossref
Ergun Nacarkucuk, Halil Saglam & Mehmet Okan. (2004) Meropenem Decreases Serum Level of Valproic Acid. Pediatric Neurology 31:3, pages 232-234.
Crossref
Crossref
Scott W Sinner & Allan R Tunkel. (2004) Antimicrobial agents in the treatment of bacterial meningitis. Infectious Disease Clinics of North America 18:3, pages 581-602.
Crossref
Crossref
Kassa Ayalew, Sumati Nambiar, Yuliya Yasinskaya & Barbara A. Jantausch. (2003) Carbapenems in Pediatrics. Therapeutic Drug Monitoring 25:5, pages 593-599.
Crossref
Crossref
P.J. Gavin, M.T. Suseno, F.V. Cook, L.R. Peterson & R.B. ThomsonJrJr. (2003) Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin. Diagnostic Microbiology and Infectious Disease 47:2, pages 427-430.
Crossref
Crossref
S. Parodi, A. Lechner, R. Osih, P. Vespa & D. Pegues. (2003) Nosocomial Enterobacter Meningitis: Risk Factors, Management, and Treatment Outcomes. Clinical Infectious Diseases 37:2, pages 159-166.
Crossref
Crossref
Wendelin K Nelson, Priscilla A Rayback, Ralph Quinones & Roger H Giller. (2016) Empiric Carbapenem Monotherapy in Pediatric Bone Marrow Transplant Recipients. Annals of Pharmacotherapy 36:9, pages 1360-1365.
Crossref
Crossref
Barbara S. KoppelW. Allen HauserChrissoula PolitisDavid Van Duin & Michael Daras. (2002) Seizures in the Critically Ill: The Role of Imipenem. Epilepsia 42:12, pages 1590-1593.
Crossref
Crossref
Katherine M. Knapp & B.Keith English. (2001) Carbapenems. Seminars in Pediatric Infectious Diseases 12:3, pages 175-185.
Crossref
Crossref
Burke A. Cunha. (2001) NOSOCOMIAL PNEUMONIA. Medical Clinics of North America 85:1, pages 79-114.
Crossref
Crossref
Florian Thalhammer & Walter H. H??rl. (2000) Pharmacokinetics of Meropenem in Patients with Renal Failure and Patients Receiving Renal Replacement Therapy. Clinical Pharmacokinetics 39:4, pages 271-279.
Crossref
Crossref
Matthew N. Lowe & Harriet M. Lamb. (2000) Meropenem. Drugs 60:3, pages 619-646.
Crossref
Crossref
C. Verwaest. (2000) Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clinical Microbiology and Infection 6:6, pages 294-302.
Crossref
Crossref
Miriam Hurst & Harriet M. Lamb. (2000) Meropenem. Drugs 59:3, pages 653-680.
Crossref
Crossref
S. Ragnar Norrby. (2000) Carbapenems in Serious Infections. Drug Safety 22:3, pages 191-194.
Crossref
Crossref